Gregg Gilbert
Stock Analyst at Truist Securities
(2.26)
# 2,801
Out of 5,090 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $12.76 | +33.23% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $47.91 | -22.77% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $52.15 | +61.07% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,010.31 | -48.04% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.85 | +89.78% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $12.11 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $99.72 | -6.74% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $31.20 | +53.85% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.20 | +2,066.67% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.79 | +18,887.34% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $13.44 | +480.36% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $118.65 | -34.26% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $28.46 | -36.75% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $169.70 | +3.12% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $226.08 | -70.81% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $12.76
Upside: +33.23%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $47.91
Upside: -22.77%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $52.15
Upside: +61.07%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,010.31
Upside: -48.04%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.85
Upside: +89.78%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $12.11
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $99.72
Upside: -6.74%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $31.20
Upside: +53.85%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.20
Upside: +2,066.67%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.79
Upside: +18,887.34%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $13.44
Upside: +480.36%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $118.65
Upside: -34.26%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $28.46
Upside: -36.75%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $169.70
Upside: +3.12%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $226.08
Upside: -70.81%